M5717 + pyronaridine

M5717 + pyronaridine is an **investigational antimalarial combination therapy** under preclinical and clinical development for the treatment of malaria. It combines M5717, a small molecule inhibitor of *Plasmodium* eukaryotic translation elongation factor 2 (eEF2), with pyronaridine, a benzonaphthyridine derivative that inhibits hemozoin formation in the parasite. M5717 acts by blocking parasite protein synthesis and has activity against both blood and liver stages. Pyronaridine acts rapidly, disrupting heme detoxification. The combination is being developed to exploit complementary mechanisms: M5717’s slow but broad multistage activity with pyronaridine’s fast-acting clearance and ability to suppress the emergence of resistance. The two drugs show additive antimalarial effects, no detrimental pharmacodynamic or pharmacokinetic interactions, and potent activity against *Plasmodium* blood and liver stages in preclinical models. Clinical development is ongoing for use in malaria, especially for drug-resistant *P. falciparum* infection[1][2][3][4][5].